Access to Therapies During COVID-19

/
/
Access to Therapies During COVID-19

This webpage gives information about accessing FDA approved therapies available through our Corporate Advisory Board members during the era of COVID-19. For specific questions about these therapies please reach out to the company directly using the contact information listed below. We will keep this page updated as new information becomes available.

BioMarin

Name of medication/therapy: Brineura
Drug/therapy Indication: CLN2
Changes to accessing drug/therapy during COVID-19: No changes to accessing the drug
How to get more information: Brineura.com
Webpage link: Brineura.com

 

Eisai

Name of medication/therapy: Fycompa
Drug/therapy Indication: FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged 4 and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older.
Changes to accessing drug/therapy during COVID-19: If you are a patient who has experienced loss of healthcare benefits as a result of COVID-19, you may be eligible to benefit from a temporary expansion of Eisai’s Patient Assistance Programs. Eisai has modified its Patient Assistance Program eligibility criteria temporarily in order to provide support during this crisis to those who qualify.
How to get more information: Call us at 1-855-EISAI-4-U(1-855-347-2448) to learn more.
Webpage link: https://www.eisaireimbursement.com/patient/fycompa

 

Greenwich Biosciences

Name of medication/therapy: Epidiolex
Drug/therapy Indication: Seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome in patients 2 years of age and older
Changes to accessing drug/therapy during COVID-19: At this time, we are extending our Copay Savings Program to offer commercially insured patients $0 copays for prescriptions filled between April 1, 2020 and September 30, 2020. In addition, there will be no annual savings cap for the 2020 calendar year. Greenwich Biosciences also offers support for eligible patients with no insurance or not enough insurance to cover their prescription. Patients and caregivers, including those whose situations have changed as a result of the COVID-19 pandemic, can access available resources through the Epidiolex Engageâ„¢ program.
How to get more information: Visit https://www.epidiolex.com/engage-patient-support  or contact Epidiolex Engage at 1-833-GBNGAGE (1-833-426-4243).    Patients and caregivers can also follow us on like and follow us on Facebook @EPIDIOLEX
Webpage link: https://www.epidiolex.com/engage-patient-support

 

Horizon Therapeutics

Name of medication/therapy: ACTIMUNNE, PROCYSBI, RAVICTI
Drug/therapy Indication: Chronic Granulomatous Disease, Cystinosis, Urea Cycle Disorder
Changes to accessing drug/therapy during COVID-19: None
How to get more information: [email protected]
Webpage link: www.HorizonTherapeutics.com

 

Neurelis, Inc.

Name of medication/therapy: VALTOCO® (diazepam nasal spray)
Drug/therapy Indication: VALTOCO® (diazepam nasal spray) was approved by the U.S. Food and Drug Administration (FDA) on January 10, 2020, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.
Changes to accessing drug/therapy during COVID-19: Neurelis has partnered with Maxor Specialty Pharmacy as their Early Access Partner. Maxor offers the following resources –

  • Delivery to the patient’s home or place of employment
  • Copay assistance
  • Insurance claim processing and prior authorization support
  • 24/7 access to a pharmacist

Neurelis offers a variety of product access programs to support patients –

Copay Assistance Program

  • Neurelis offers a copay program for commercially insured patients in which eligible patients may pay as low as $20 for their prescription. Patients are encouraged to discuss this program with Maxor Specialty Pharmacy during the collection of copay and scheduling of delivery of their VALTOCO prescription. Maxor will proactively offer assistance if there are any identified affordability issues. Patients can contact Maxor at 1-866-629-6779 for additional information.

Patient Assistance Program

  • Neurelis offers assistance to patients who are uninsured through the Patient Assistance Program. Patient’s are encouraged to contact myNEURELIS for additional information on how to apply for this program. myNEURELIS can be reached by calling 1-866-myNEURELIS (1-866-696-3873)

Clinical Trial Transition Program

  • Neurelis has chosen to support those patients who contributed to the clinical development program. If the patient’s physician chooses to prescribe them VALTOCO, Neurelis offers a program to ensure these patients receive product if there is a delay in coverage by their primary insurance plan. Maxor Specialty Pharmacy will work with myNEURELIS to coordinate and support the patient in getting access to VALTOCO in both the short term and long term.

VALTOCO® REPLACMENT PROGRAM

  • Neurelis, Inc. understands the unique needs and unpredictable nature of epilepsy. In managing seizure cluster episodes, it is difficult to know when, or even if, this type of seizures occurs and when they would require treatment. It is important to have a rescue therapy on-hand to stop these type of seizure episodes as quickly as possible, however we know that there may be considerable time between episodes. To ensure peace of mind for patients and caregivers, Neurelis currently offers a VALTOCO Replacement Program that ensures all patients who receive VALTOCO can receive replacement product at no charge in the event they do not use their product before it expires. This program is offered through Maxor Specialty Pharmacy. The Replacement Program is provided at no cost to the patient or third-party payers. Patients can follow the simple steps below.

Patients call Maxor Specialty Pharmacy at 866.629.6779 once their product is within 15 days of expiring. Maxor will ship product overnight directly to the patient to the location of their choice at no charge on an agreed upon date. For more information patients can contact Maxor at 866.629.6779. Maxor also has in place a program in which they will proactively reach out to patients to make them aware of the Replacement Program.
How to get more information: www.valtoco.com or www.myNEURELIS.com

 

UCB, Inc.

Name of medication/therapy: BRIVIACT® (brivaracetam) CV
Drug/therapy Indication: BRIVIACT® (brivaracetam) CV is a prescription medicine that can be used to treat partial-onset (focal) seizures in people 4 years of age and older. It is not known if BRIVIACT injection is safe for use in children. Children 4 years of age and older should only take BRIVIACT by mouth. BRIVIACT injection is only for use in people 16 years of age and older and may be given in the vein (intravenously) when BRIVIACT is not able to be taken by mouth. It is not known if BRIVIACT is safe and effective in children younger than 4 years of age.
Changes to accessing drug/therapy during COVID-19: We have expanded our existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19 by expediting enrollment to help ensure uninterrupted access to their medicines at no cost. This change will help patients experiencing difficulty affording UCB medicines due to job loss, job furlough, or loss of insurance coverage during this unprecedented time. Contact ucbCARES at (844) 599-CARE (2273) or by email at [email protected] to see if you qualify for medicines at no cost.
How to get more information: Contact ucbCARES at (844) 599-CARE (2273) or by email at [email protected]
Webpage link: https://www.ucb-usa.com/Patients/Patients

 

Name of medication/therapy: NAYZILAM® (midazolam) nasal spray, CIV
Drug/therapy Indication: NAYZILAM® (midazolam) nasal spray, CIV is a prescription medicine used for the short-term treatment of seizure clusters (also known as acute repetitive seizures) in patients 12 years of age and older. It is a rescue medication in the form of a nasal spray.
Changes to accessing drug/therapy during COVID-19: We have expanded our existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19 by expediting enrollment to help ensure uninterrupted access to their medicines at no cost. This change will help patients experiencing difficulty affording UCB medicines due to job loss, job furlough, or loss of insurance coverage during this unprecedented time. Contact ucbCARES at (844) 599-CARE (2273) or by email at [email protected] to see if you qualify for medicines at no cost.
How to get more information: Contact ucbCARES at (844) 599-CARE (2273) or by email at [email protected]
Webpage link: https://www.ucb-usa.com/Patients/Patients

 

Name of medication/therapy: VIMPAT® (lacosamide) CV
Drug/therapy Indication: VIMPAT® (lacosamide) CV is a prescription medicine used to treat partial-onset seizures in people 4 years of age and older. It is not known if VIMPAT injection is safe for use in children. Children age 4 years and older should only take VIMPAT by mouth. VIMPAT injection is only for use in people 17 years of age and older. It is not known if VIMPAT is safe and effective in children under 4 years of age.
Changes to accessing drug/therapy during COVID-19: We have expanded our existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19 by expediting enrollment to help ensure uninterrupted access to their medicines at no cost. This change will help patients experiencing difficulty affording UCB medicines due to job loss, job furlough, or loss of insurance coverage during this unprecedented time. Contact ucbCARES at (844) 599-CARE (2273) or by email at [email protected] to see if you qualify for medicines at no cost.
How to get more information: Contact ucbCARES at (844) 599-CARE (2273) or by email at [email protected]
Webpage link: https://www.ucb-usa.com/Patients/Patients

Start typing and press Enter to search

Shopping Cart